Table 2.
Description of the mutational status of the 90 patients with advanced non-small cell lung cancer included in the study.
Mutation Status | Retrospective Cohort [N = 60] | Prospective Cohort [N = 30] |
---|---|---|
No detected mutations | 25 (42%) | 5 (17%) |
Mutations detected in | 33 (55%) | 25 (83%) |
EGFR | 9 (15%) | 8 (27%) |
KRAS | 20 (33%) | 13 (43%) |
BRAF | 3 (5%) | 2 (7%) |
Double Mutations | ||
EGFR del19 & KRAS p.G12D | 1 (2%) | na |
EGFR p.V774M & p.L861Q | na | 1 (3%) |
EGFR p.L858R & p.G719C | na | 1 (3%) |
Failed analysis | 2 (3%) | na |